After intravitreal injections, do you continue to use topical antibiotics?
Keywords:
Intravitreal injection; Steroid; Anti-vascular endothelial growth factor (VEGF); Topical antibiotic; Enodphthalmitis; Antibiotic resistance.Abstract
Nowadays intravitreal drug injection is the most frequent treatment for retinal diseases. Despite widely use endophthalmitis is
already most feared complication of every intravitreal injection in each patient. In clinical setting topical antibiotics have been
widely used as a precaution to prevent endophthalmitis however recent published evidence showed it to be unnecessary. Furthermore repeated use of topical antibiotics might give rise to antibiotic resistance in conjunctival flora and thus more aggressive endophthalmitis. Strict asepsis has been awarded as the main rule for endophthalmitis prophylaxis intravitreal injection.
References
Campbell RJ, Bronskill SE, Bell CM, Paterson JM, Whitehead M, Gill SS. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: A population–based analysis. Arch Ophthalmol. 2010; 128(3): 359-362. doi: 10.1001/archophthalmol.2010.19
Keenan TD, Wotton CJ, Goldacre MJ. Trends over time and geographical variation in rates of intravitreal injections in England. Br J Ophthalmol. 2012; 96(3): 413-418. doi: 10.1136/bjophthal-mol-2011-300338
Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreal injections. Retina. 2004; 24(5 Suppl): S3-S19. doi: 10.1097/00006982-200410001-00002
Genentech Inc. Lucentis 10mg/ml solution for injection. high-lights of prescribing information. San Francisco, CA, USA. Web site. https://www.medicines.org.uk/emc/product/307/smpc. Ac-cessed September 22, 2016.
Sigford DK, Reddy S, Moolineaux C, Schaal S. Global report-ed endophthalmitis risk following intravitreal injections of anti-VEGF: A literature review and analysis. Clin Ophthalmol. 2015; 9: Öztürk BT 773-781. doi: 10.2147/OPTH.S77067
DossarpsD, Bron AM, Koehrer P, Aho-Glele LS, Creuzot-Garcher C, FRCR net. Endophthalmitis after intravitreal injections: incidence, presentation, management and visual outcome. Am J Ophthalmol. 2015; 160(1): 17-25e1. doi: 10.1016/j.ajo.2015.04.013
McCannel CA. Meta-analysis of endophthalmitis after intravit-real injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies. Retina. 2011; 31(4): 654-661. doi: 10.1097/IAE.0b013e31820a67e4
Mosfeghi AA, Rosenfeld PJ, Flynn JW Jr, et al. Endophthalmi-tis after intravitreal vascular [corrected] endothelial growth factor antagonists: A six year experience at a university referral center. Retina. 2011; 31(4): 662-668. doi: 10.1097/IAE.0b013e31821067c4
Bhavsar AR, Googe JM, Stockdale CR, et al. Risk of endo-phthalmitis after intravitreal drug injection when topical antibiotics are not required: The diabetic retinopathy clinical research network laser-ranbizumab-triamcinolone clinical trials. Arch Ophthalmol. 2009; 127(12): 1581-1583. doi: 10.1001/archophthalmol.2009.304
Mason JO 3rd, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina. 2008; 28(4): 564-567. doi: 10.1097/ IAE.0b013e3181633fee
Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmtiis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008; 145(5): 879- 882. doi: 10.1016/j.ajo.2007.12.036
Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endo-phthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008; 28(10): 1395-1399. doi: 10.1097/ IAE.0b013e3181884fd2
Hunyor AP, Merani R, Darbar A, Korobelnik JF, Lanzetta P, Okada AA. Topical antibiotics and intravitreal injections. Acta Oph-thalmol. 2018; 96(5): 435-441. doi: 10.1111/aos.13417
Halachmi–Eyal O, Lang Y, Keness Y, Miron D. Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povi-done iodine 5% alone to reduce bacterial colonization in the con-junctival sac. J Cataract Refract Surg. 2009; 35(12): 2109-2114. doi: 10.1016/j.jcrs.2009.06.038
Moss JM, Sanislo SR, Ta CN. A prospective randomized evalu-ation of topical gatifloxacin on conjunctival flora in patients un-dergoing intravitreal injections. Ophthalmology. 2009; 116(8): 1498-
Benoistd’Azy C, Pereira B, Naughton G, Chiambaretta F, Dutheil F. Antibioprophylaxis in prevention of endophthalmitis in intravitreal injection: A systematic review and meta-analysis. PLoS One. 2016; 11(6): e0156431. doi: 10.1371/journal.pone.0156431
Bhavsar AR, Stockdale CR, Ferris FL 3rd, et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol. 2012; 130(6): 809-810. doi: 10.1001/archophthalmol.2012.227
Bhatt SS, Stephen KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: Effect on endophthalmitis rate. Retina. 2011; 31(10): 2032-2036. doi: 10.1097/IAE.0b013e31820f4b4f
Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endopthalmitis and use of antibiotic prohylaxis after intravitreal injections. Ophthalmology. 2012; 119(8): 1609-1614. doi: 10.1016/j.ophtha.2012.02.014
Falavarjani KG, Modarres M, Hashemi M, et al. Incidence of acute endophthalmitis after intravitrealbevacizumab injection in a single clinical center. Retina. 2013; 33(5): 971-974. doi: 10.1097/ IAE.0b013e31826f0675
Storey P, Dollin M, Pitcher J, et al. The role of topical an-tibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014; 121(1): 283-289. doi: 10.1016/j.oph-tha.2013.08.037
Bhavsar AR, Sandler DR. Eliminating antibiotic prophylaxis for intravitreal injections: A consecutive series of 18839 injections by a single surgeon. Retina. 2015; 35(4): 783-788. doi: 10.1097/ IAE.0000000000000392
Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitidunal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol. 2011; 129(9): 1180-1188. doi: 10.1001/archophthalmol.2011.213
Meredith TA, McCannel CA, Barr C, et al. Postinjectionendo-phthalmitis in the comparison of age-related macular degeneration treatment trials (CATT). Ophthalmology. 2015; 122(4): 817-821. doi: 10.1016/j.ophtha.2014.10.027
Gupta A, Sun JK, Silva PS. Complications of intraviter-ous injections in patients with diabetes. 2018; 33(1): 42-50. doi: 10.1080/08820538.2017.1353811
Stem MS, Todorich B, Yonekawa Y, Capone A Jr, Williams GA, Ruby AJ. Incidence and Visual Outcomes of Culture-Proven Endophthalmitis Following Dexamethasone Intravitreal Implant. JAMA 2017; 135(4): 379-382.
Menchini F, Toneatto G, Miele A, Donati S, Lanzetta P, Vir-gili G. Antibiotic prophylaxis for preventing endophthlamitis after intravitreal injection: A systematic review. Eye (Lond). 2018; 32(9): 1423-1431. doi: 10.1038/s41433-018-0138-8
Li AL, Wykoff CC, Wang R, et al. Endophthalmitis af-ter intravitreal injection: Role of prophylactic topical ophthal-mic antibiotics. Retina. 2016; 36(7): 1349-1356. doi: 10.1097/ IAE.0000000000000901 8 Öztürk BT
St Leger AJ, Desai VJ, Drummond RA, et al. An ocular com-mensal protects against corneal infection by driving an interleu-kin-17 response from mucosal γδ T cells. Immunity. 2017; 47(1): 148-158. doi: 10.1016/j.immuni.2017.06.014
Dave SB, Toma HS, Kim SJ. Changes in ocular flora in eyes ex-posed to ophthalmic antibiotics. Ophthalmology. 2013; 120(5): 937-
Kim SJ, Toma HS, Midha NK, Cherney EF, Recchia FM, Doherty TJ. Antibiotic resistance of conjunctiva and nasopharynx evaluation study: A prospective study of patients undergoing in-travitreal injections. Ophthalmology. 2010; 117(12): 2372-2378. doi: 10.1016/j.ophtha.2010.03.034
Trimawithana TR, Young S, Bunt CR, Green C, Alany RG. Drug delivery to the posterior segment of the eye. Drug Discov To-day. 2011; 16(5-6): 270-277. doi: 10.1016/j.drudis.2010.12.004
Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina. 2006; 26(2): 191-195. doi: 10.1097/00006982-200602000-00012
Hsu J. Minimizing the risk of endophthalmitis after injection. Ophthalmol Retina. 2019; 3(1): 1-2. doi: 10.1016/j.oret.2018.10.011
Hsu J, Gerstenblith AT, Garg SJ, Vander JF. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections with-out postinjection topical antibiotics. Am J Ophtalmol. 2014; 157(3): 514-518. doi: 10.1016/j.ajo.2013.10.003
Lanker Klossner B, Widmer HR, Frey F. Nondevelopment of resistance by bacteria during hospital use of povidone-iodine. Der-matology. 1997; 195(Suppl 2): 10-13. doi: 10.1159/000246024
Friedman DA, Mason III JO, Emond T, MsGwinJr G. Po-vidone-iodine contact time and lid speculum use during in-travitreal injection. Retina. 2013; 33(5): 975-981. doi: 10.1097/ IAE.0b013e3182877585
Levinson JD, Garfunkel RA, Berinstein DM, et al. Timing of povidone iodine application to reduce the risk of endophthalmitis after intravitreal injections. Ophthalmol Retina. 2018; 2(7): 654-658. doi: 10.1016/j.oret.2017.06.004
Koemer JC, George MJ, Meyer DR, et al. Povidone-iodine con-centration and dosing in cataract surgery. Surv Ophthalmol. 2018; 63(6): 862-868. doi: 10.1016/j.survophthal.2018.05.002
Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal in-jection technique and monitoring: updated guidelines of an expert panel. Retina. 2014; 34 Suppl 12: S1-S18. doi: 10.1097/ IAE.0000000000000399
Diabetic Retinopathy Clinical Research Network. Scott IU, Ed-wards Ar, et al. A phase II randomized, clinical trial of intravitreal for diabetic macular edema. Ophthalmology. 2007; 114(10): 1860-
Royal College of Ophthalmologists. Age-related macu-lar degeneration: Gıidelines for management. Web site. http:// www.rcophth.ac.uk/wp-content/uploads/2014/12/2013-SCI-318-RCOphth-AMD-Guidelines-Sept-2013-FINAL-2.pdf. Ac-cessed September 22, 2016.
American Academy of Ophthalmology. How to give intra-vitreal injections. Web site. https://www.aao.org/eyenet/article/ how-to-give-intravitreal-injections. Accessed September 22, 2016.
American Academy of Ophthalmology. Five things physicians and patients should question. Web site. http://www.choosingwise-ly. Org/societies/american-academy-of-ophthalmology/. Released February 21, 2013. Accessed September 22, 2016.
Meyer CH, Mennel S, Eter N. Endophthalmitis rate mit und ohnetopische post-operative antibiotikgabe nach intravitrealer Avastin-Injektion. Der Ophthalmologe. 2007; 104(11): 952-957. doi: 10.1007/s00347-007-1634-6
Casparis H, Wolfensberger TJ, Becker M, et al. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: A retrospective multicenter study. Retina. 2014; 34(1): 12-17. doi: 10.1097/IAE.0b013e31829f74b0 Submit your article to this journal | https://openventio.org/submit-manuscript/ Öztürk BT
Ramel JC, Bron AM, Isaico R, Meillon C, Binquet C, Creuzot-Garcher C. Incidence of endophthalmitis after intravitreal injec-tion: is antibiotic prophylaxis mandatory? J Fr Ophthalmol. 2014; 37(4): 273-279. doi: 10.1016/j.jfo.2014.01.003
Stranak Z, Veith M, Studeny P, Pencak M. The incidence of endophtalmitis after the application of intravitreal injections in FNKV with regard to various prophylactic antibiotic regimens [In: Czech]. Ceska Slov Oftalmol. 2014; 70(5): 184-188.
FalavarjaniKG, Aghamirsalim M, Modarres M, et al. Endo-phthalmitis after resident-performed intravitreal bevacizumab injection. Can J Ophthalmol. 2015; 50(1): 33-36. doi: 10.1016/j. jcjo.2014.09.005
Pachuo MA, Sahto AA, Quraishi MH, Abbasi AM. Role of post-injection antibiotics after intravitrealbevacizumab injection in preventing endophthalmitis. Pak J Ophthalmol. 2015; 31: 41-47.
Bhavsar AR, Glassman AR, Stockdale CR, Jampol LM, Dia-betic Retinopathy Clinical Research Network. Elimination of topical antibiotics for intravitreous injections and the importance of using povidone-iodine: Update from the DRCR.net. JAMA Ophthalmol. 2016; 134(10): 1181-1183. doi: 10.1001/jamaophthal-mol.2016.2741
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in The Ophthalmology (TOOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.